Assistant Professor of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital
Obstetrics & Gynecology
Dr. Neil S. Horowitz, MD
|
|
Give Review
Doctor Neil S. Horowitz, MD is an expert in the field of Obstetrics & Gynecology. He graduated from Duke University School of Medicine. Duke University School of Medicine is a top medical college. Duke University School of Medicine is ranked 8/29 in Research/PrimaryCare. He received 1 awards: "Meaningful Use Stage 1 Certification". Neil S. Horowitz, MD is a published doctor. He has 61 papers published. The most current publication "Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva." He is registered with Medicare.
Publications
- Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
- Optimal management of low-risk gestational trophoblastic neoplasia.
- Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced stage Müllerian Cancer.
- Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell Carcinoma of the vulva?
- Epithelioid trophoblastic tumor: A single institution case series at the New England Trophoblastic Disease Center.
- Does Aggressive Surgery Improve Outcomes? Interaction Between Preoperative Disease Burden and Complex Surgery in Patients With Advanced-Stage Ovarian Cancer: An Analys...
- Erratum to: Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer.
- Evidence for a Dualistic Model of High-grade Serous Carcinoma: BRCA Mutation Status, Histology, and Tubal Intraepithelial Carcinoma.
- Drug-induced death signaling strategy rapidly predicts Cancer response to chemotherapy.
- Clinical characteristics and outcomes of patients with stage I epithelial ovarian Cancer compared to fallopian tube Cancer.
- Complications of Pelvic radiation in patients treated for gynecologic malignancies.
- Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenoCarcinoma: a gynecologic oncology group study.
- Anesthetic Selection and Disease-Free Survival Following Optimal Primary Cytoreductive Surgery for Stage III Epithelial Ovarian Cancer.
- Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial Carcinoma.
- Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial Cancer: A SEER analysis.
- Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous Carcinoma of the ovary.
- A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial Cancer.
- Upper abdominal procedures in advanced stage ovarian or primary peritoneal Carcinoma patients with minimal or no gross residual disease: An analysis of Gynecologic Onc...
- Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian Cancer.
- A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal Carcinoma.
- Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian Carcinoma.
- Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?
- Young women diagnosed with early-stage ovarian Cancer or borderline malignancy of the ovary: a focus on fertility and sexual function.
- A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia.
- Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal Cancers treated with intraperitoneal chemotherapy.
- Prognostic determinants in patients with uterine and ovarian clear Carcinoma.
- Prognostic Determinants in Patients With Stage I Uterine Papillary Serous Carcinoma: A 15-Year Multi-Institutional Review.
- Management of adnexal masses in pregnancy.
- Should stage IIIC ovarian Cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: A Gynecologic Oncology Group study.
- Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer.
- Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
- Carcinosarcoma of the ovary: A case-control study.
- ACR appropriateness criteria© ovarian Cancer screening.
- Prognostic determinants in patients with stage IIIC and IV uterine papillary serous Carcinoma.
- Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
- Management of gestational trophoblastic neoplasia.
- Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
- Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian Cancer.
- Decreased survival in EGFR gene amplified vulvar Carcinoma.
- PET-CT vs. CT alone in ovarian Cancer recurrence.
- Novel cytotoxic agents from an unexpected source: bile acids and Ovarian tumor apoptosis.
- Evaluating adnexal lesions: which need follow-up?
- Profiling microdissected epithelium and stroma to model genomic signatures for Cervical carcinogenesis accommodating for covariates.
- Healing of vulvo-Vaginal radionecrosis following revascularization.
- Uterine malignant mixed mullerian tumors should not be included in studies of endometrial Carcinoma.
- CA-125 response in patients with recurrent ovarian or primary peritoneal Cancer treated with pegylated liposomal doxorubicin or topotecan.
- Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.
- Advances in the surgical management of ovarian Cancer.
- Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus Cancer.
- The role of topotecan for extending the platinum-free interval in recurrent ovarian Cancer: an in vitro model.
- Adequate staging for uterine Cancer can be performed through Pfannenstiel incisions.
- Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial Cancer?
- Primary peritoneal Carcinoma presenting as adenoCarcinoma on a Pap smear. A case report.
- Placental site trophoblastic tumor presenting with a pneumothorax during pregnancy.
- The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies.
- Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients.
- Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial Carcinoma.
- Endometrial stromal sarcoma: a clinicopathologic study of 29 patients.
- Comparison of outcomes in patients with early-stage mucinous endometrial Cancer and those with endometrioid endometrial Cancer, with and without adjuvant therapy.
- Prognostic determinants in patients with uterine and Ovarian carcinosarcoma.
Schools
Duke University School Of Medicine
Cancer Center New York
University Of Wa Med Center Seattle
Wa University Barnes Jewish Hospital Mo
Procedures Preformed
- Colporrhaphy
- Colposcopy
- Destruction or Excision of Vaginal Lesions
- EndoCervical Curettage
- View All
Conditions Treated
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- Cervical Polyps
- View All
Doctors Specialties
- Gynecologic Oncology
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
University of Washington -
Duke University School of Medicine
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1629050919 | |
| NPPES Provider LastName | HOROWITZ | |
| NPPES Provider FirstName | NEIL | |
| NPPES Provider ZIPCode | 021156110 | |
| NPPES Provider State | MA | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 66.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1629050919 |
| Last Name Of The Provider | HOROWITZ |
| First Name Of The Provider | NEIL |
| View All |
Similar Doctors
|
|
Dr. Annekathryn Goodman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Boruta II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason A. Knight, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Rachel M. Clark, MD |
|
|
Dr. Sarah Feldman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Khady Diouf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Whitfield B. Growdon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nancy S. Miller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Young B. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John Durfee, MD
This Doctor is OpenDoctor Recommended.
|